DailyIQ
|
Sector:HealthcareAll sectors
Last updated 2 minutes ago

BSX·Boston Scientific Corporation

$.
-. (-.%)
After Hours
High
$50.15
Open
$49.45
Market Cap
72.16B
52W High
$109.50
Low
$48.27
P. Close
$48.55
P/E
20.24
52W Low
$47.16
Fwd P/E
58.45
DailyIQ Est.
$93.47
Technical Score (1D)
27
SELL
News Sentiment
44
BEARISH
Boston Scientific reported Q1 revenue of $5.20 billion, up 11.6 % year‑over‑year and beating estimates. However, the company trimmed near‑term and full‑year guidance because Watchman stroke‑prevention sales are slowing amid intensifying competition. The guidance cut signals potential pressure on future earnings, which may temper the recent rally that outpaced the S&P 500. Investors will now focus on whether the firm can sustain its core cardiac product momentum while the Watchman segment falters. The revised outlook could compress valuation multiples and shift the trading range for the next 1–10 days. Analysts note that the company’s full‑year guidance still projects EPS of $3.37 and revenue of $21.64 billion, but the Watchman slowdown introduces uncertainty. Watch for the upcoming earnings release to see if guidance is further revised or if Watchman sales rebound. Additionally, monitor competitive developments in the cardiac device market that could accelerate the Watchman decline. Finally, keep an eye on any analyst estimate revisions that may adjust the stock’s valuation in the near term.
Earnings Summary
Boston Scientific Corporation (BSX) is a global medical device manufacturer headquartered in Marlborough, Massachusetts, specializing in interventional medical specialties across gastrointestinal, urological, neurological, chronic pain, and cardiovascular segments. The company’s portfolio includes devices for coronary artery disease, aortic valve conditions, heart rhythm management, and peripheral arterial disease, positioning it firmly within the high‑margin medical devices sector. In the most recent quarters, Boston Scientific has consistently outperformed analyst expectations, with EPS of $0.70 in Q4 2024 versus an estimate of $0.66 and $0.75 in Q1 2025 versus $0.67, while revenue rose to $4.56 billion and $4.66 billion respectively; the trend continued with $5.06 billion in Q2 2025 and $5.07 billion in Q3 2025, both beating estimates of $5.05 billion and $5.06 billion, and $5.29 billion in Q4 2025 versus an estimate of $5.33 billion, a slight revenue shortfall but an EPS of $0.80 versus $0.79; Q1 2026 revenue of $5.20 billion exceeded the $5.17 billion estimate and EPS of $0.80 beat the $0.79 estimate, underscoring a pattern of earnings resilience amid modest revenue volatility. Historically, the company has maintained a streak of EPS beats across eight consecutive quarters, with revenue growth remaining positive but decelerating from a 10.6 % YoY increase in Q1 2025 to a 0.6 % rise in Q1 2026; the consistent EPS outperformance contrasts with occasional revenue misses, suggesting a robust cost‑management framework. Recent news highlights a slowdown in Watchman stroke‑prevention sales, prompting a trimmed near‑term guidance and a price‑target cut from $80 to $65 by BTIG, while a $6 billion share buyback and the FRACTURE IDE trial reinforce the coronary portfolio; these developments signal potential short‑term valuation compression and a strategic pivot toward cost efficiency and emerging therapeutic areas. Investors should watch for any further guidance revisions, the trajectory of Watchman sales, regulatory milestones for the SEISMIQ 4CE device, and the timing of the buyback tranches, as these factors will shape the next earnings cycle and influence valuation dynamics.

EPS

EstBeatMiss
$0.65$0.70$0.75$0.80$0.85Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$0.83 - -
Q1'26$0.79$0.80+1.6%
Q4'25$0.79$0.80+1.6%
Q3'25$0.71$0.75+5.1%
Q2'25$0.73$0.75+3.4%
Q1'25$0.67$0.75+11.5%

Revenue

EstBeatMiss
$4.5B$4.8B$5.0B$5.3B$5.6BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$5.4B - -
Q1'26$5.2B$5.2B+0.6%
Q4'25$5.3B$5.3B-0.9%
Q3'25 - $5.1B -
Q2'25 - $5.1B -
Q1'25 - $4.7B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

BSX Stock Snapshot

BSX is currently trading at $48.49, giving Boston Scientific Corporation a market cap of 72.16B and a P/E ratio of 20.2. Today's range spans $48.27–$50.15, with shares opening at $49.45 and moving down $0.06 (0.1%) from the prior close. DailyIQ's technical score sits at 27/100 (SELL) with a news sentiment reading of 44/100.

Over the past year BSX has traded between $47.16 and $109.50 - the current price is +2.8% off the 52-week low and -55.7% from the high. 42 analysts cover the stock with a Buy consensus and a mean 12-month target of $78.17 (range $55.00–$106.00), implying upside of +61.2%.

Risk is elevated for Boston Scientific Corporation (BSX) right now - bearish technical setup (27/100, SELL), neutral sentiment (44/100), price $48.49 (near 52-week lows). The current P/E ratio stands at 20.2. At 72.16B in Healthcare market cap, the 52-week range of $47.16–$109.50 defines where structural demand might resurface - because at this capitalization tier, buyers don't disappear, they just move their bids to different price levels.

When a large-cap Healthcare name with 72.16B in capitalization prints a SELL signal (27/100) alongside neutral news sentiment (44/100), the risk isn't just price depreciation — it's the loss of institutional sponsorship that makes recovery harder. At $48.49 (near 52-week lows in the $47.16–$109.50 range), the structural support levels are where that sponsorship question gets answered.